Table 2.

Breast cancer risk associated with CYP1B1 and COMT genotypes, the Shanghai Breast Cancer Study

All subjects
Premenopausal women
Postmenopausal women
CaseControlOR (95% CI)*CaseControlOR (95% CI)CaseControlOR (95% CI)
CYP1B1
    Codon 48
        Arg/Arg7407651.00 (reference)4944811.00 (reference)2432811.00 (reference)
        Arg/Gly3463860.93 (0.78-1.11)2302520.89 (0.71-1.11)1141330.99 (0.73-1.34)
        Gly/Gly37470.81 (0.52-1.27)25300.81 (0.47-1.40)12170.82 (0.38-1.74)
Interaction,* P = 0.848
    Codon 119
        Ala/Ala7397901.00 (reference)4925011.00 (reference)2442861.00 (reference)
        Ala/Ser3493721.00 (0.84-1.20)2332410.98 (0.79-1.23)1141301.03 (0.76-1.39)
        Ser/Ser36500.77 (0.50-1.20)25320.80 (0.47-1.36)11180.72 (0.33-1.55)
Interaction, P = 0.945
    Codon 432
        Leu/Leu8399011.00 (reference)5555671.00 (reference)2803301.00 (reference)
        Val/Leu2482671.09 (0.61-1.95)1711771.02 (0.52-2.01)76901.35 (0.42-4.30)
        Val/Val23271.09 (0.62-1.92)18191.03 (0.54-1.99)581.36 (0.44-4.20)
Interaction, P = 0.916
COMT
        Val/Val6126281.00 (reference)4144061.00 (reference)1952201.00 (reference)
        Val/Met4254700.93 (0.78-1.10)2762980.91 (0.73-1.12)1471710.97 (0.72-1.30)
        Met/Met83930.92 (0.67-1.26)56551.00 (0.67-1.48)27370.82 (0.48-1.40)
Interaction, P = 0.749
  • * The ORs (95% CIs) and P values for the interaction test were derived from logistic models.